Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ACTRN12626001131347) titled 'TUT-CIP-002: A Pivotal, Multicenter, Open-label, Randomized Controlled Trial to Evaluate the Effectiveness and Safety of Tutelix™ TL150 (IOP40), a Thermoresponsive Hydrogel Spacer for Prostate Radiotherapy' on Sept. 11.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Open (masking not used)
Assignment: Parallel
Primary Sponsor: Tutelix Pty Ltd
Condition:
Prostate Cancer
Prostate Cancer
Cancer - Prostate
Intervention:
Tutelix™ is a water-based solution of a proprietary synthetic polymer with rheological characteristics similar to w...